Vertex Pharmaceuticals: Buy, Sell, or Hold?
Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now hitting the $100 billion mark, has it become too expensive of an investment? Is it time for investors to consider other stocks instead, or can Vertex still be a good buy right now?
Let's dive in and take a look.
Vertex Pharmaceuticals has become a big name in cystic fibrosis (CF) treatments. And that's where the company makes its money, with blockbuster drug Trikafta/Kaftrio bringing in $8.9 billion in revenue last year. Its growth rate did slip, however, from 35% in 2022 to just 16% in 2023.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€448.50
0.990%
The stock is one of the favorites of our community with 58 Buy predictions and 2 Sell predictions.
With a current price of 448.5 € Vertex Pharmaceuticals Inc. is right around the predicted target price of 450 €.
